................................ ........ 62 3.3. MTD Definition .......................................................................................................63 3.4. Toxicities Observed in the Expansion Phase ..........................................................63 3.5. Recommended Part 2 Expansion Dose Definition ..................................................63 4. PARTI CIPANT ELIGI BILITY CRITERIA ........................................................................63 4.1. I nclusion Criteria .....................................................................................................64 4.1.1. Part 1 I nclusion Criteria ..............................................................................64 4.1.2. Part 2 I nclusion Criteria ..............................................................................65 4.2. Part 1 Exclusion Criteria .........................................................................................67 4.2.1. Part 1 Exclusion Criteria .............................................................................67 4.2.2. Part 2 Exclusion Criteria .............................................................................71 4.3. L ifesty le Requirements (Part 1 and Part 2) .............................................................74 4.4. Sponsor’s Qualified Medical Personnel ..................................................................75 5. STUDY TREATMENTS .....................................................................................................75 5.1. Allocation to Treatment ..........................................................................................76 5.2. Participant Compliance ...........................................................................................76 5.3. I nvestigational Product Supplies .............................................................................77 5.3.1. Dosage Form(s) and Packaging ..................................................................77 5.3.2. Preparation and Dispensing ........................................................................78 5.4. Administration .........................................................................................................78 5.4.1. Recommended Dose Modifications ............................................................79 5.4.2. Dosing Interruptions/Delay s due to Treatment Related Toxicity ...............80 5.4.3. If these conditions are met within 2 weeks of treatment interruption or cy cle delay , investigational product(s) may be resumed. Refer to section Dosing Interruptions/Delay s due to Non- Related Events ....................80 5.4.4. Dosing Interruptions/Delay s due to Non -Related Events ...........................81 5.4.5. Dose Reductions .........................................................................................81 5.4.5.1. A dC68 Dose Reductions ...........................................................82 5.4.5.2. Tremelimumab Dose Reductions ..............................................82 5.4.5.3. Sasanlimab Dose Reductions ....................................................83 PF-06936308 C3621001 Final Protocol Amendment 2, 22 Dec 2020 PFIZER CONFIDENTIAL Page 85.5. I nvestigational Product Storage ..............................................................................85 5.6.